- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
All New Products Listed Chronologically
| 製品コード | 製品名称 | 製品説明 | 添加時期 |
|---|---|---|---|
| F6860 | Ezrin Antibody [L20P21] | May 19 2026 | |
| F9697 | TRAF5 Antibody [C3D23] | May 19 2026 | |
| F3474 | Cubilin C-terminal Antibody [C16H20] | May 19 2026 | |
| F4893 | HSF1 Antibody [H19A5] | May 19 2026 | |
| F4797 | TFEB Antibody [G16A13] | May 19 2026 | |
| F7041 | Fragilis Antibody [E3D3] | May 19 2026 | |
| F5116 | NAPRT1 Antibody [H9L14] | May 19 2026 | |
| F2980 | Ferritin Light Chain Antibody [N3B24] | May 19 2026 | |
| F5148 | HuD Antibody [M19B4] | May 19 2026 | |
| F7739 | Calponin 3 Antibody [N11H14] | May 19 2026 | |
| F2941 | UCH37 Antibody [P22L1] | May 19 2026 | |
| F8319 | Mer Antibody [M17J16] | May 19 2026 | |
| F4663 | Estrogen Related Receptorα Antibody [H18K23] | May 19 2026 | |
| F6623 | PRMT6 Antibody [K2N19] | May 19 2026 | |
| F4709 | CAB39/MO25 Antibody [H1E9] | May 19 2026 | |
| F9066 | ATPIF1 Antibody [L4C2] | May 19 2026 | |
| F5477 | RPL11 Antibody [K10D6] | May 19 2026 | |
| F8609 | Ceruloplasmin Antibody [K22D1] | May 19 2026 | |
| F4856 | Cyclin T1 Antibody [L16J22] | May 19 2026 | |
| F8283 | TAB2 Antibody [E6J10] | May 19 2026 | |
| F4815 | CD19 Antibody [H7K12] | May 19 2026 | |
| F2740 | TRAP1 Antibody [H11J13] | May 19 2026 | |
| F6195 | PHB2 Antibody [P5A22] | May 19 2026 | |
| F4906 | ITK Antibody [H23L5] | May 19 2026 | |
| F6834 | SHMT2/SHMT Antibody [H9N23] | May 19 2026 | |
| F7263 | 14-3-3 eta/YWHAH Antibody [H13P22] | May 19 2026 | |
| F8168 | HDAC7 Antibody [P6D17] | May 19 2026 | |
| F1409 | Phospho-EGF Receptor (Tyr998) Antibody [L7A22] | May 19 2026 | |
| F4853 | JMJD2A Antibody [G6B24] | May 19 2026 | |
| F7767 | SHIP2 Antibody [D4N9] | May 19 2026 | |
| F9725 | RCC1 Antibody [J20J20] | May 19 2026 | |
| F7079 | IL-2Rβ/p75 Antibody [D16J3] | May 19 2026 | |
| F9881 | C Reactive Protein Antibody [N20E9] | May 19 2026 | |
| F4313 | β-1,4-Gal-T1 Antibody [C2J8] | May 19 2026 | |
| F4513 | SR-2A Antibody [L13G15] | May 19 2026 | |
| F8277 | PRMT7 Antibody [F2F1] | May 19 2026 | |
| F5640 | SIRPα/SHPS1 Antibody [B15C11] | May 19 2026 | |
| F8393 | Fibulin 3 Antibody [G19N6] | May 19 2026 | |
| F2409 | CaMKIIδ Antibody [E8P2] | May 19 2026 | |
| F4590 | TREM2 Antibody [F18K20] | May 19 2026 | |
| F4905 | p95/NBS1 Antibody [P16D23] | May 19 2026 | |
| F5070 | DMT1/SLC11A2 Antibody [C16J1] | May 19 2026 | |
| F9646 | DDX3 Antibody [J24G2] | May 19 2026 | |
| F9196 | RED1 Antibody [L7J8] | May 19 2026 | |
| F5494 | Serine racemase Antibody [A1N23] | May 19 2026 | |
| F5758 | FGF-23 Antibody [B12L4] | May 19 2026 | |
| F5011 | RALA Antibody [G17M6] | May 19 2026 | |
| F5023 | Phospho-SLP-76 (Ser376) Antibody [D2F12] | May 19 2026 | |
| F5024 | MAVS Antibody [H8N11] | May 19 2026 | |
| F4528 | Phospho-RPA32/RPA2 (Ser4/8) Antibody [M17K6] | May 19 2026 | |
| F4952 | ESRRB Antibody [H9C3] | May 19 2026 | |
| F1642 | SV40 T-antigen Antibody [C12F2] | May 19 2026 | |
| F2749 | HSD3B2 Antibody [J9K21] | May 19 2026 | |
| F1126 | CTGF Antibody [P10H5] | May 19 2026 | |
| F2916 | Syntaxin Antibody [K5F22] | May 19 2026 | |
| F0972 | Toll-like Receptor 9 Antibody [K21F2] | May 19 2026 | |
| F3843 | BMP7 Antibody [J15D7] | May 19 2026 | |
| F5129 | ECHS1 Antibody [N10G4] | May 19 2026 | |
| F6753 | Flightless I Antibody [N3K8] | May 19 2026 | |
| F4911 | Mad2L1 Antibody [L3N17] | May 19 2026 | |
| F6715 | MLX Antibody [N17K22] | May 19 2026 | |
| F0798 | Phospho-Elk-1 (Ser383) Antibody [P22B17] | May 19 2026 | |
| F8764 | 53BP1 Antibody [E7B6] | May 19 2026 | |
| F8879 | Phospho-GEF-H1 (Ser886) Antibody [E24J19] | May 19 2026 | |
| F6628 | GOPC Antibody [D5A8] | May 19 2026 | |
| F6681 | INPP4B Antibody [H1L5] | May 19 2026 | |
| F5176 | Tau Antibody [G23J10] | May 19 2026 | |
| F2214 | Fibroblast Activation Protein α Antibody [A9L24] | May 19 2026 | |
| F3385 | IRS-1+IRS-2 Antibody [P5F13] | May 19 2026 | |
| F0807 | Phospho-ABL1 (Tyr245) Antibody [F15J16] | May 19 2026 | |
| F7385 | SIN3A Antibody [B10N4] | May 19 2026 | |
| F8928 | Arp3 Antibody [N13C13] | May 19 2026 | |
| F9211 | IDH2 Antibody [P11N22] | May 19 2026 | |
| F5456 | hnRNP A2B1 Antibody [A10M11] | May 19 2026 | |
| F8459 | SCG10/Stathmin-2 Antibody [F16M4] | May 19 2026 | |
| F4982 | ANP32A Antibody [D12M13] | May 19 2026 | |
| F6852 | SAM68 Antibody [E2F14] | May 19 2026 | |
| F7071 | SMC3 Antibody [D14N5] | May 19 2026 | |
| F5041 | MRP4/ABCC4 Antibody [E23K18] | May 19 2026 | |
| F7704 | ALDH1A3 Antibody [J5E20] | May 19 2026 | |
| F8862 | FGF-19 Antibody [L9N16] | May 19 2026 | |
| F8212 | HLA-G Antibody [K12D7] | May 19 2026 | |
| F7338 | Phosphoribosyl Pyrophosphate Amidotransferase Antibody [M15J4] | May 19 2026 | |
| F7894 | CNOT7 Antibody [N8J19] | May 19 2026 | |
| F6171 | Munc18-1 Antibody [G23A10] | May 19 2026 | |
| F9875 | NRBF2 Antibody [E16A8] | May 19 2026 | |
| F7654 | ALDH2 Antibody [C21F15] | May 19 2026 | |
| F1298 | Phospho-Insulin Receptor β (Tyr1345) Antibody [L11H12] | May 19 2026 | |
| F7166 | OTUB1 Antibody [N21M4] | May 19 2026 | |
| F2475 | GBA Antibody [K1P17] | May 19 2026 | |
| F5912 | PZR Antibody [F15F10] | May 19 2026 | |
| F6710 | cIAP Pan-specific Antibody [B1J9] | May 19 2026 | |
| F9281 | Cytochrome C Oxidase subunit VIc/COX6C Antibody [C2A20] | May 19 2026 | |
| F3704 | CXCL5 + CXCL6 Antibody [P8L5] | May 19 2026 | |
| F9496 | Na Channel β1 Subunit Antibody [F4D21] | May 19 2026 | |
| F5118 | PFN2 Antibody [A7F23] | May 19 2026 | |
| F5209 | PDE4B Antibody [A23H17] | May 19 2026 | |
| F7934 | TIM 1 Antibody [M14A22] | May 19 2026 | |
| F5386 | HSP47 Antibody [D19M10] | May 19 2026 | |
| F5659 | MCT4/SLC16A3 Antibody [D23C24] | May 19 2026 | |
| F8272 | DAP12 Antibody [E15J7] | May 19 2026 | |
| F7769 | HLA E Antibody [G19G18] | May 19 2026 | |
| F2902 | Phospho-HER2/ErbB2 (Tyr1139) Antibody [L15E14] | May 19 2026 | |
| F6890 | TDRD3 Antibody [C20J18] | May 19 2026 | |
| F4739 | HDAC5 Antibody [B2J1] | May 19 2026 | |
| F5561 | SELS Antibody [N9D15] | May 19 2026 | |
| E5828 | GSK205 | May 18 2026 | |
| E6741 | SB-405483 | May 18 2026 | |
| L2060 | Customize Library（compound antibody kit） | May 13 2026 | |
| E0859 | Aminoxyacetic acid | Aminoxyacetic acid (AOAA) is an inhibitor of malate–aspartate shuttle (MAS) that effectively suppresses MAS activity in cells. It also induces both early‑ and late‑stage apoptosis of resting and LPS‑activated microglia and impairs their energy metabolism. | May 12 2026 |
| E6553 | BMS-986463 | BMS-986463, a CRBN E3 ligase modulator (CELMoD), is a WEE1 kinase molecular glue degrader that significantly inhibits tumor growth and reduces phospho‑CDK2 levels in preclinical models. | May 12 2026 |
| E6771 | Bretisilocin | Bretisilocin (GM‑2505) is an agonist of 5‑HT2A receptor and 5‑HT releaser that is under development for the treatment of major depressive disorder (MDD). | May 12 2026 |
| E6677 | CATPB | CATPB is an antagonist of FFA2R that inhibits the transient rise in intracellular Ca²⁺ induced in neutrophils by acetate or the synthetic FFAR2 agonist Cmp1, thereby blocking downstream FFAR2‑dependent activation responses, including NADPH oxidase–derived superoxide production. | May 12 2026 |
| E6745 | Igermetostat | Igermetostat (XNW5004) is potent and selective, substrate‑competitive inhibitor of EZH2 that effectively targets both wild‑type and mutant EZH2, leading to marked reduction of H3K27me3, G1/S cell‑cycle arrest, and apoptosis in tumor cells. | May 10 2026 |
| E0862 | Leucylleucine methyl ester | Leucylleucine methyl ester is a lysosomotropic dipeptide that is taken up into leukocyte lysosomes via a dipeptide‑specific transport system and cleaved by the granule enzyme dipeptidyl peptidase I (cathepsin C) into hydrophobic oligomers, which disrupt intracellular membranes and selectively kill cytotoxic lymphocytes and other DPPI‑high cells, with species‑dependent sensitivity of B cells (murine B cells sensitive, human B cells largely resistant). | May 10 2026 |
| E6695 | 3α-Aminocholestane | 3-α-aminocholestane is a selective inhibitor of enzymatic activity of INPP5D (SHIP1), an enzyme with a role in controlling immune regulatory cell numbers in vivo, with an IC50 of ~2.5 μmol/l. | May 08 2026 |
| E6516 | L-Glutamine-13C5 | L-Glutamine-13C5 is a stable isotope-labeled form of the non-essential amino acid L-glutamine, where all five carbon atoms are replaced with the isotope^13C. It is primarily used as a tracer in mass spectrometry (LC-MS, GC-MS) or NMR for investigating metabolic pathways, protein synthesis, and cellular nutrient utilization, particularly in cancer research. | May 08 2026 |
| E6462 | IAMA-6 | IAMA‑6 (ARN23746) is a potent, selective, and orally bioavailable inhibitor of the NKCC1 cotransporter. It exhibits the potential to be primarily used in research to treat cognitive impairment in Down syndrome and autism by regulating intracellular chloride homeostasis. | May 07 2026 |
| E6718 | Polfurmetinib | Polfurmetinib(MEK-IN-6,PF-07799544,ARRY-134) (compound 69) is a potent and selective inhibitor of MEK that potently suppresses ERK1/2 phosphorylation at Thr202/Tyr204 in A375 melanoma cells with an IC50 of 2 nM. | May 06 2026 |
| E6737 | flizasertib | flizasertib (GDC-8264) is orally active, reversible, and selective inhibitor of receptor-interacting protein kinase 1 (RIP1), exhibiting Ki app values of 0.00071 μM against human RIP1 and 0.0013 μM against cynomolgus monkey RIP1. | May 06 2026 |
| E6733 | Adrixetinib TFA | Adrixetinib TFA(Q702 TFA) is an orally active, selective triple kinase inhibitor of CSF1R, Mer, and Axl receptors within the TAM (Tyro3/Axl/Mer), exhibiting Kd of 8.7 nM (CSF1R), 0.8 nM (Mer), and 0.3 nM (Axl). It also binds the ATP-binding pockets of these RTKs to block ligand-induced autophosphorylation, disrupting downstream PI3K/Akt and Gas6-mediated survival signaling while repolarizing tumor-associated macrophages from pro-tumorigenic M2 to anti-tumor M1 phenotypes. | May 06 2026 |
| E6732 | Mesutoclax | Mesutoclax (ICP-248) (Compound 5) is a potent, orally bioavailable, and selective inhibitor of BCL-2 with an IC50 of 1.54 nM demonstrating weak activity against BCL-XL with an IC50 > 1000 nM. | May 05 2026 |
| E5965 | BMS-986458 | BMS-986458 is a potent, highly selective, orally bioavailable CRL4 CRBN E3 ubiquitin ligase-dependent BCL6 ligand directed degrader, which exhibits the potential to treat B-cell non-Hodgkin Lymphoma. | May 05 2026 |
| E6729 | RGH-857 | RGH-857 (compound 51) is an orally active positive allosteric modulator (PAM) of the nicotinic α7 acetylcholine (α7 nACh) receptor with an EC50 of 34 nM for human α7 nAChR and demonstrating exceptional potency and efficacy in preclinical models of cognitive impairment. | May 05 2026 |
| E6713 | BLU-808(SAR449028) | BLU-808 (SAR449028) is a potent and selective inhibitor of wild‑type c‑KIT and potently inhibits c‑KIT–dependent phosphorylation and proliferation. It also exhibits therapeutic benefit to patients suffering from wild‑type c‑KIT–mediated mast cell disorders. | Apr 28 2026 |
| E6569 | MD-4251 | MD‑4251 is an orally active PROTAC degrader of MDM2. It potently degrades MDM2 in RS4;11 cells with a DC50 of 0.2 nM and activates p53. | Apr 28 2026 |
| E0865 | DFHBI-1T | DFHBI‑1T is a membrane‑permeable, non‑toxic fluorogenic probe that acts as a ‘light‑up’ sensor for RNA imaging in live cells. It specifically binds to RNA aptamers such as Broccoli, Spinach, and Spinach2, yielding strong green fluorescence with high signal‑to‑noise ratios. | Apr 28 2026 |
| E6494 | ATR-258 | ATR‑258 (Compound 15) is a specific agonist of GRK‑biased β2‑adrenergic receptor (β2AR) with a pEC50 of 6.87 that increases glucose uptake with low cAMP generation. | Apr 27 2026 |
| E6773 | Olorofim(F901318) | Olorofim (F901318) is a reversible inhibitor of dihydroorotate dehydrogenase (DHODH), an oxidoreductase that catalyzes the fourth step in the de novo synthesis of pyrimidines. It exhibits potential for the treatment of invasive mold infections and thermally dimorphic fungi that are refractory to or resistant to clinically available antifungals. | Apr 26 2026 |
| E6776 | AP-503 | AP‑503 is a selective agonist of GPR133/ADGRD1 with an EC50 of 1.21 nM. It exhibits the potential to be used in research on the prevention of muscle‑related diseases and vestibular dysfunction. | Apr 26 2026 |
| E6582 | LysoTracker Red(LysoTracker Red DND-99) | LysoTracker Red (LysoTracker Red DND-99) is an acidotropic, red-fluorescent probe (Ex/Em 577/590 nm) that selectively stains lysosomes and late endosomes in live cells. As a hydrophobic weak base, it freely diffuses across membranes at neutral pH (~7.4), becomes protonated in acidic compartments (pH 4.5-6.0), and traps via charge retention, preventing efflux for high-contrast imaging. | Apr 23 2026 |
| E5849 | KT-253 | KT-253 (Seldegamadlin) is a potent, selective heterobifunctional MDM2 degrader with a DC50 of 0.4 nM and p53 stabilizer. It also exhibits antitumor activity across p53 wild-type hematologic and solid tumors. | Apr 23 2026 |
| E6528 | BBT-176 | BBT-176 is a first-in-class reversible fourth-generation EGFR TKI with potent activity against osimertinib-resistant mutations with an IC50 of 49 nM (Del19/T790M/C797S), 202 nM (L858R/T790M/C797S), 42 nM (Del19/C797S), and 183 nM (L858R/C797S) in Ba/F3 cells. | Apr 21 2026 |
| E6738 | BCFTP | BCFTP is a potent, orally active, selective positive allosteric modulator (PAM) of human MrgprX1 that enhances endogenous ligand signaling to inhibit spinal C-fibre nociceptive transmission, thereby relieving heat hyperalgesia and spontaneous pain in neuropathic models without itch or tolerance. | Apr 21 2026 |
| E6663 | DDO-02267 | DDO‑02267 is a selective, lysine‑targeting covalent inhibitor of ALKBH5, with an IC50 of 0.49 μM. DDO‑02267 increases m⁶A levels and targets the ALKBH5–AXL signaling axis in AML cells. It exhibits the potential to serve as a chemical probe for investigating the biological function of the mRNA demethylase ALKBH5. | Apr 21 2026 |
| A2179 | Anti-Mouse CD41-Invivo | Apr 20 2026 | |
| E1270 | Afimetoran( BMS-986256) | Afimetoran (BMS-986256) is an orally active and selective antagonist of TLR7/8 that potently inhibits NF-κB activation and reverses TLR7-mediated steroid resistance in pDCs. | Apr 19 2026 |
| E0874 | Ulotaront hydrochloride | Ulotaront hydrochloride (SEP-363856 hydrochloride) is an orally active, CNS-penetrant psychotropic agent that acts as an agonist of the trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor. It acts as an antipsychotic and used for the treatment of schizophrenia. | Apr 19 2026 |
| E0873 | Niacin hydrochloride | Niacin hydrochloride (Nicotinic acid; Vitamin B3) is a direct and noncompetitive inhibitor of hepatocyte diacylglycerol acyltransferase–2(DGAT2), a key enzyme for TG synthesis, which results in accelerated intracellular hepatic apo B degradation and the decreased secretion of VLDL and LDL particles. | Apr 19 2026 |
| E6631 | Oxamic acid | Oxamic acid (Oxamate) is a classical inhibitor of lactate dehydrogenase‑A (LDH‑A) that competitively blocks the conversion of pyruvate to lactate. It also induces G2/M arrest and apoptosis, and increases radiosensitivity in nasopharyngeal carcinoma cells. | Apr 16 2026 |
| E6711 | ACI-19626 | ACI‑19626 (TDP‑43‑IN‑2) is a first‑in‑class, small‑molecule PET tracer that specifically binds to pathological TDP‑43 aggregates, which are key drivers of neurodegeneration in diseases such as ALS, FTD, and LATE. | Apr 16 2026 |
| F5646 | MLANA/MART-1 Antibody [D21A21] | Apr 15 2026 | |
| F7400 | SOX17 Antibody [F21M23] | Apr 15 2026 | |
| F6403 | Phospho-Rad17 (Ser645) Antibody [D14D16] | Apr 15 2026 | |
| F8643 | APC1 Antibody [C16G2] | Apr 15 2026 | |
| F8114 | CYP1B1 Antibody [C13E23] | Apr 15 2026 | |
| F6430 | RPA70/RPA1 Antibody [N23A19] | Apr 15 2026 | |
| F6358 | UQCRFS1/RISP Antibody [P24M17] | Apr 15 2026 | |
| F7268 | GRIM19 Antibody [J7L19] | Apr 15 2026 | |
| F7378 | Pax6 Antibody [H2K10] | Apr 15 2026 | |
| F0677 | Cre Recombinase Antibody [D11J17] | Apr 15 2026 | |
| F4845 | γTubulin (Centrosome Marker) Antibody [D14G7] | Apr 15 2026 | |
| F5052 | BLNK Antibody [L16M19] | Apr 15 2026 | |
| F5066 | CD147 Antibody [D10H20] | Apr 15 2026 | |
| F5071 | IKKα Antibody [B4D5] | Apr 15 2026 | |
| F5068 | Toll-like Receptor 9 Antibody [M15F23] | Apr 15 2026 | |
| F5119 | PRMT2 Antibody [G16H19] | Apr 15 2026 | |
| F5081 | eIF4B Antibody [D13A19] | Apr 15 2026 | |
| F5596 | eEF1A Antibody [P21C20] | Apr 15 2026 | |
| F5039 | c-Rel Antibody [B22C17] | Apr 15 2026 | |
| F4973 | ZEB2 Antibody [J21B10] | Apr 15 2026 | |
| F4914 | TBP Antibody [B18N3] | Apr 15 2026 | |
| F5065 | T-bet/TBX21 Antibody [B10M22] | Apr 15 2026 | |
| F4391 | PSF Antibody [M17A24] | Apr 15 2026 | |
| F7337 | SMC2 Antibody [P11C8] | Apr 15 2026 | |
| F6237 | TACE Antibody [A22J10] | Apr 15 2026 | |
| F7512 | OS9 Antibody [M17H4] | Apr 15 2026 | |
| F9508 | FUNDC1 Antibody [A14J2] | Apr 15 2026 | |
| F8457 | WDR59 Antibody [P9B16] | Apr 15 2026 | |
| F9839 | Phospho-Tau (Thr205) Antibody [J19P9] | Apr 15 2026 | |
| F7572 | MLLT1/ENL Antibody [N21N24] | Apr 15 2026 | |
| F7840 | NDUFB8 Antibody [B17H14] | Apr 15 2026 | |
| F8463 | TRIM5α Antibody [E3H20] | Apr 15 2026 | |
| F6281 | Phospho-Lck (Tyr505) Antibody [P3K14] | Apr 15 2026 | |
| F8509 | Cytochrome b Antibody [F15F24] | Apr 15 2026 | |
| F7381 | ABCA7 Antibody [A11M15] | Apr 15 2026 | |
| F9941 | OGDH Antibody [F21L21] | Apr 15 2026 | |
| F7802 | GFI1 Antibody [M16D23] | Apr 15 2026 | |
| F6554 | GFI1b Antibody [B12K19] | Apr 15 2026 | |
| F5114 | MTA2 Antibody [P2H17] | Apr 15 2026 | |
| F6714 | SPHK2 Antibody [A21H5] | Apr 15 2026 | |
| F6626 | Legumain Antibody [N22H22] | Apr 15 2026 | |
| F7735 | SirT4 Antibody [C24N9] | Apr 15 2026 | |
| F6883 | RBM15 Antibody [L5G12] | Apr 15 2026 | |
| F7055 | PARG Antibody [B20B2] | Apr 15 2026 | |
| F7320 | Phospho-CAD (Ser1859) Antibody [C23K19] | Apr 15 2026 | |
| F8602 | LCP1 Antibody [P20F21] | Apr 15 2026 | |
| F6401 | Mili Antibody [K20L16] | Apr 15 2026 | |
| F7214 | α-Parvin Antibody [P1L24] | Apr 15 2026 | |
| F8644 | RBL1 Antibody [M18D3] | Apr 15 2026 | |
| F7848 | CXXC5 Antibody [L11K10] | Apr 15 2026 | |
| F8647 | DHCR24/Seladin-1 Antibody [L8J15] | Apr 15 2026 | |
| F7745 | SPT6 Antibody [P6D2] | Apr 15 2026 | |
| F8255 | EphA3/A4/A5 Antibody [A18J10] | Apr 15 2026 | |
| F5151 | FANCA Antibody [J21M8] | Apr 15 2026 | |
| F5584 | Phospho-LYN (Y397)/LCK (Y394)/HCK (Y411)/BLK (Y389) Antibody [G2C4] | Apr 15 2026 | |
| F9786 | Phospho-MOB1 (Thr12) Antibody [F15P10] | Apr 15 2026 | |
| F6347 | SMRT Antibody [M7D13] | Apr 15 2026 | |
| F4132 | Src Antibody [L10F23] | Apr 15 2026 | |
| F4322 | DEC1 Antibody [D7J6] | Apr 15 2026 | |
| F4373 | KRAS Antibody [A18C4] | Apr 15 2026 | |
| F4399 | Phospho-MBP (Thr98) Antibody [A3B1] | Apr 15 2026 | |
| F4401 | Keratin Epithelial Antibody [J4M17] | Apr 15 2026 | |
| F4676 | Nicastrin Antibody [D2C5] | Apr 15 2026 | |
| F4527 | MTP Antibody [J4K3] | Apr 15 2026 | |
| F4721 | PAR2 Antibody [J17G12] | Apr 15 2026 | |
| F5275 | MAD2L2 Antibody [P22A23] | Apr 15 2026 | |
| F5330 | SHOC2 Antibody [H23M19] | Apr 15 2026 | |
| F4724 | Phospho-α-Synuclein (Ser129) Antibody [G19P15] | Apr 15 2026 | |
| F6154 | Asymmetric-Methyl-PABP1 (Arg455/460) Antibody [P20H17] | Apr 15 2026 | |
| F7391 | NUP153 Antibody [M17C21] | Apr 15 2026 | |
| F8050 | Hsp90β Antibody [N13J8] | Apr 15 2026 | |
| F2359 | Phospho-GSK3β (Y216)/GSK3α (Y279) Antibody [F22P22] | Apr 15 2026 | |
| F8406 | CHAF1A Antibody [G22G1] | Apr 15 2026 | |
| F6265 | Phospho-AP2M1 (Thr156) Antibody [J20G9] | Apr 15 2026 | |
| F4079 | Fas Antibody [C6C4] | Apr 15 2026 | |
| F6119 | Abi1 Antibody [D2H9] | Apr 15 2026 | |
| F5015 | CaMKK2 Antibody [P19A6] | Apr 15 2026 | |
| F5035 | SIX1 Antibody [N3M10] | Apr 15 2026 | |
| F8456 | ORC2 Antibody [P19N22] | Apr 15 2026 | |
| F5534 | Phospho-RCC1 (Ser11) Antibody [J7C7] | Apr 15 2026 | |
| F9583 | XPF Antibody [D21K23] | Apr 15 2026 | |
| F8070 | Phospho-Rpb1 CTD (Ser2/Ser5) Antibody [C1L6] | Apr 15 2026 | |
| F8979 | Phospho-Merlin (Ser518) Antibody [P22P10] | Apr 15 2026 | |
| F8224 | FAM134B Antibody [E7A17] | Apr 15 2026 | |
| F8798 | XAF1 Antibody [C23J4] | Apr 15 2026 | |
| F4773 | Chd1 Antibody [E24E7] | Apr 15 2026 | |
| F4942 | Sodium Channel Antibody [P23N9] | Apr 15 2026 | |
| F6053 | DAG Lipase β Antibody [K18L4] | Apr 15 2026 | |
| F6799 | IL-6Rα/CD126 Antibody [P8F17] | Apr 15 2026 | |
| F6381 | WAPL Antibody [B12E23] | Apr 15 2026 | |
| F8574 | LEDGF Antibody [G7D12] | Apr 15 2026 | |
| F9651 | Phospho-Myosin IIa (Ser1943) Antibody [H18C12] | Apr 15 2026 | |
| F8556 | MERIT40 Antibody [B22L22] | Apr 15 2026 | |
| F6346 | Phospho-MEK1 (Thr292) Antibody [F18G17] | Apr 15 2026 | |
| F7069 | Phospho-MCM2 (Ser139) Antibody [D19G1] | Apr 15 2026 | |
| F8573 | Sec31A Antibody [J15M23] | Apr 15 2026 | |
| F9375 | ELL Antibody [B15J21] | Apr 15 2026 | |
| F7085 | Olig2 Antibody [C6H24] | Apr 15 2026 | |
| F7845 | RRM2 Antibody [L9E5] | Apr 15 2026 | |
| F5314 | Securin Antibody [E2P20] | Apr 15 2026 | |
| F5208 | Phospho-NMDA Receptor 2B/GluN2B (Ser1303) Antibody [F24J19] | Apr 15 2026 | |
| F8982 | DUSP6/MKP3 Antibody [E9K23] | Apr 15 2026 | |
| F5399 | Phospho-eIF4E (Ser209) Antibody [G23F17] | Apr 15 2026 | |
| F6511 | Elk-1 Antibody [J24L11] | Apr 15 2026 | |
| F5914 | Claudin-5 Antibody [F16P13] | Apr 15 2026 | |
| F8411 | YY1 Antibody [M11B11] | Apr 15 2026 | |
| F5231 | FTO Antibody [P22L4] | Apr 15 2026 | |
| F9219 | NPC1 Antibody [P4H6] | Apr 15 2026 | |
| F8500 | WTAP Antibody [E21M11] | Apr 15 2026 | |
| F6946 | Lysozyme C Antibody [J12N14] | Apr 15 2026 | |
| F7924 | Fascin Antibody [K2B22] | Apr 15 2026 | |
| F6829 | Syntenin-1/MDA9 Antibody [B6B6] | Apr 15 2026 | |
| F6704 | DUSP1 Antibody [L5P15] | Apr 15 2026 | |
| F5755 | hnRNP L Antibody [G15K5] | Apr 15 2026 | |
| E6682 | CT-996(RO7795081，RG6652） | CT‑996 (RO7795081, RG6652) is an orally active, cAMP‑biased agonist of GLP‑1R with an EC50 ≈ 0.049 nM for cAMP, with minimal β‑arrestin recruitment and receptor internalization, suitable for research on type 2 diabetes and obesity. | Apr 14 2026 |
| E0863 | Talfirastide acetate | Talfirastide acetate (TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate) is an endogenous heptapeptide of the renin–angiotensin system (RAS) with a cardioprotective role due to its anti‑inflammatory and anti‑fibrotic activities in cardiac cells. It inhibits purified canine ACE activity with an IC50 of 0.65 μM and also acts as a local synergistic modulator of kinin‑induced vasodilation by inhibiting ACE and promoting nitric oxide release. | Apr 14 2026 |
| E6787 | Rineterkib hydrochloride | Rineterkib hydrochloride is an orally active, potent inhibitor of RAF and ERK1/2, exhibiting preclinical activity in multiple MAPK-activated cancer cell lines and xenograft models. | Apr 14 2026 |
| E6679 | PhIP | PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is a carcinogenic heterocyclic aromatic amine often generated in thermal processing of food. It induces DNA damage via CYP1A2 activation to hydroxylated metabolites forming C8-dG adducts and mutations. It also binds ERα to drive estrogenic signaling independent of genotoxicity, promoting epigenetic changes in MCF-7 breast cells akin to 17-β-estradiol, contributing to tissue-specific carcinogenesis in breast, colon, and prostate. | Apr 13 2026 |
| E0866 | Glycerophosphoric acid | Glycerophosphoric acid is a naturally occurring compound and an a‑site substrate analogue that, when bound to the a‑site, strongly inhibits the reaction of indole and nucleophilic indole analogues with E(A‑A). It also serves as a structural precursor of glycerophospholipids in cell membranes, contributing to membrane organization, fluidity, and transport regulation. | Apr 12 2026 |
| F0810 | Proglucagon Antibody [M22K5] | Apr 09 2026 | |
| F0978 | Bassoon/BSN Antibody [P23K9] | Bassoon,Bassoon/BSN | Apr 09 2026 |
| F1579 | CaSR Antibody [A19J6] | Calcium Sensing Receptor,Calcium-sensing R/CaSR,CaSR | Apr 09 2026 |
| F2579 | Polycystin 1/PC1 Antibody [B20F13] | Polycystin 1/PC1,Polycystin-1 | Apr 09 2026 |
| F2818 | Haptoglobin Antibody [B3H20] | Apr 09 2026 | |
| F3150 | AKT3 + AKT1 Antibody [L21G14] | Apr 09 2026 | |
| F3183 | Human IgG3 Antibody [K16P8] | Apr 09 2026 | |
| F3465 | Oxytocin-neurophysin 1 Antibody [N22P12] | Oxytocin,Oxytocin-neurophysin 1 | Apr 09 2026 |
| F3727 | Ghrelin Antibody [F2E5] | Apr 09 2026 | |
| F3871 | Phospho-Histone H2A (Ser129) Antibody [A4N9] | Apr 09 2026 | |
| F3949 | SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody [E8H21] | Apr 09 2026 | |
| F4034 | Collagen V Antibody [L8G6] | Apr 09 2026 | |
| F4167 | Phospho-ATM (Ser1981) Antibody [A4J11] | Apr 09 2026 | |
| F4101 | MRP3/ABCC3 Antibody [L20F24] | Apr 09 2026 | |
| F4238 | Phospho-NF-κB p65 (Ser529) Antibody [F5A1] | Apr 09 2026 | |
| F4672 | GAP43 Antibody [P10H20] | Apr 09 2026 | |
| F4665 | Cre Recombinase Antibody [E18L5] | Apr 09 2026 | |
| F4096 | ARID1B/BAF250B Antibody [M24N11] | Apr 09 2026 | |
| F4326 | Phospho-MBS/MYPT1 (Thr696) Antibody [K5H5] | Apr 09 2026 | |
| F7839 | Phospho-Atg14 (Ser29) Antibody [B12C19] | Apr 09 2026 | |
| F3703 | Aquaporin 2 Antibody [N16N24] | AQP2,Aquaporin 2,Aquaporin 2/AQP2,Aquaporin-2 | Apr 09 2026 |
| F4481 | HPV18 E6 Antibody [C18N16] | Apr 09 2026 | |
| F4898 | Fibronectin Antibody [P19B9] | Apr 09 2026 | |
| F4812 | Phospho-MST1/MST2 (T180 + T183) Antibody [B24N16] | Apr 09 2026 | |
| F4046 | CDKN2A/p14ARF Antibody [A5L13] | Apr 09 2026 | |
| F4747 | CD11c Antibody [J2H17] | Apr 09 2026 | |
| F4807 | PKCθ/PRKCQ Antibody [L3H13] | Apr 09 2026 | |
| F4693 | Atg9A Antibody [L22J4] | Apr 09 2026 | |
| F5095 | LPCAT3 Antibody [H3J6] | Apr 09 2026 | |
| F4153 | Phospho-Jak2 (Tyr1007/1008) Antibody [L12G1] | Apr 09 2026 | |
| F4097 | RARα Antibody [M12K22] | Apr 09 2026 | |
| F6719 | SGK3 Antibody [D18P23] | Apr 09 2026 | |
| F3713 | ENPP2/ATX Antibody [J20P19] | Apr 09 2026 | |
| F3702 | Thrombopoietin Antibody [H8L15] | Apr 09 2026 | |
| F5131 | GMFβ Antibody [C17A8] | Apr 09 2026 | |
| F4409 | Protein A Antibody [B17N6] | Apr 09 2026 | |
| F5093 | NTF2 Antibody [A24B24] | Apr 09 2026 | |
| F1004 | NuMA Antibody [K18C4] | Apr 09 2026 | |
| F1108 | RSK1 p90 Antibody [K1J12] | RSK1,RSK1 p90 | Apr 09 2026 |
| F4981 | HDAC11 Antibody [H19H1] | Apr 09 2026 | |
| F9884 | TBC1D1 Antibody [C20L8] | Apr 09 2026 | |
| F0323 | Caspase9 Antibody [A3K12] | Caspase 9,Caspase-9,caspase-9 p35 | Apr 09 2026 |
| F9936 | DCP1B Antibody [L22N5] | Apr 09 2026 | |
| F1567 | Lysozyme Antibody [D18K12] | Apr 09 2026 | |
| F1254 | MMP-1 Antibody [C7E21] | MMP1,MMP-1 | Apr 09 2026 |
| F3400 | Fas Antibody [D2F4] | Apr 09 2026 | |
| F4687 | PARK7/DJ1 Antibody [D23K10] | Apr 09 2026 | |
| F4003 | SLC12A3 Antibody [G5P18] | Apr 09 2026 | |
| F4145 | TBK1/NAK Antibody [C14L9] | Apr 09 2026 | |
| F5000 | DDB1 Antibody [M17E15] | Apr 09 2026 | |
| F4688 | HuR/ELAVL1 Antibody [G18B5] | Apr 09 2026 | |
| F2309 | ATP1B1 Antibody [A23C23] | ATP1B1,beta 1 Sodium Potassium ATPase/ATP1B1,Na,K-ATPase β1,Na+/K+ ATPase beta 1,Sodium Potassium ATPase Beta 1 | Apr 09 2026 |
| F2480 | Phospho-Src (Tyr419) Antibody [D21H6] | Phospho-SRC (Tyr419),Src (phospho Y419) | Apr 09 2026 |
| F2499 | Phospho-RAB8A (Thr72) Antibody [A18L3] | Apr 09 2026 | |
| F2481 | Tyrosinase Antibody [P8H17] | Apr 09 2026 | |
| F5796 | Radixin Antibody [C5B23] | Apr 09 2026 | |
| F9843 | UBR5 Antibody [A19C24] | Apr 09 2026 | |
| F1200 | MLKL Antibody [M19F23] | Apr 09 2026 | |
| F5044 | CRBN Antibody [P23M10] | Apr 09 2026 | |
| F5062 | Ubc12 Antibody [K5G17] | Apr 09 2026 | |
| F5069 | ERG Antibody [N14M7] | Apr 09 2026 | |
| F5033 | ATP6V1B2 Antibody [K16G16] | Apr 09 2026 | |
| F5244 | Sec24C Antibody [L6M24] | Apr 09 2026 | |
| F5260 | TNFRSF8/CD30 Antibody [G5N10] | Apr 09 2026 | |
| F5857 | S100B Antibody [P12F20] | Apr 09 2026 | |
| F5342 | Profilin-1 Antibody [P24C16] | Apr 09 2026 | |
| F5947 | Cathepsin D Antibody [H1J11] | Apr 09 2026 | |
| F8918 | GPNMB Antibody [J15J20] | Apr 09 2026 | |
| F6976 | Angiomotin Antibody [M16G16] | Apr 09 2026 | |
| F8174 | Histone H3 (mono methyl K9) Antibody [G13B9] | Apr 09 2026 | |
| F4077 | c-Kit Antibody [D16J9] | Apr 09 2026 | |
| F4720 | YB1 Antibody [J2K10] | Apr 09 2026 | |
| F3618 | ME2 Antibody [B19K5] | Malic Enzyme 2,ME2 | Apr 09 2026 |
| F8890 | CtBP1 Antibody [J24B2] | Apr 09 2026 | |
| F7974 | TH1L Antibody [N21A8] | Apr 09 2026 | |
| F8990 | WT1 Antibody [J23C5] | Apr 09 2026 | |
| F6287 | HMGN2 Antibody [F23H15] | Apr 09 2026 | |
| F5082 | Granzyme B Antibody [A1B9] | Apr 09 2026 | |
| F7112 | PRMT5 Antibody [M17F9] | Apr 09 2026 | |
| F6128 | CYP17A1 Antibody [G22K11] | Apr 09 2026 | |
| F7867 | ADAR1 Antibody [E16C6] | Apr 09 2026 | |
| F6456 | Glutaminase1/GLS1 Antibody [A10K11] | Apr 09 2026 | |
| F7448 | SMG-1 Antibody [L4N6] | Apr 09 2026 | |
| F5996 | UQCRC2 Antibody [C21D5] | Apr 09 2026 | |
| F9819 | APC11 Antibody [G19D9] | Apr 09 2026 | |
| F5827 | JARID1C Antibody [J9D7] | Apr 09 2026 | |
| F9572 | Phospho-ALK (Tyr1507) Antibody [P14J22] | Apr 09 2026 | |
| F6889 | PAF1 Antibody [D19B13] | Apr 09 2026 | |
| F6373 | Nav1.5 Antibody [G4B10] | Apr 09 2026 | |
| F8484 | GGA3 Antibody [M2J4] | Apr 09 2026 | |
| F8231 | PGK1 Antibody [H17D18] | Apr 09 2026 | |
| F7853 | FABP4 Antibody [H23L13] | Apr 09 2026 | |
| F5289 | PHD3 Antibody [H19K23] | Apr 09 2026 | |
| F8492 | SMYD3 Antibody [P23D23] | Apr 09 2026 | |
| F7513 | TIPE2 Antibody [A15H13] | Apr 09 2026 | |
| F4890 | β2 Microglobulin Antibody [D17A9] | Apr 09 2026 | |
| F4980 | KIF15 Antibody [M12M19] | Apr 09 2026 | |
| F4999 | METTL14 Antibody [A8N22] | Apr 09 2026 | |
| F5049 | PKCβ Antibody [B15A17] | Apr 09 2026 | |
| F3142 | Acetyl-p53 (Lys120) Antibody [P22N5] | Apr 09 2026 | |
| E6546 | PF-07899895 | PF-07899895 (Compound 34) is an inhibitor of SIK, with an IC50 of 1.2 nM, 0.9 nM, and 1.8 nM for SIK1, SIK2, and SIK3, respectively. It also modulates the anti-inflammatory cytokine IL-10 in immune cells and exhibits potential applicable research related to inflammatory diseases. | Apr 08 2026 |
| E6742 | Z218484536 | Z218484536 is a selective and brain-penetrant inhibitor of phosphoserine phosphatase (PSPH) that binds to PSPH with a Kd of approximately 0.23 μM. | Apr 08 2026 |
| E0858 | Lavofloxacin lactate | Lavofloxacin lactate, the lactate salt of levofloxacin, is a fluoroquinolone antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, leading to double-strand DNA breaks and bacterial cell death. | Apr 08 2026 |
| E1034 | PKH26 | PKH26 is a red fluorescent lipophilic dye (Ex/Em = 551/567 nm) that stably integrates into the lipid bilayer of cell membranes via its long aliphatic hydrocarbon tails, enabling long-term tracking without significant cytotoxicity or transfer between cells. | Apr 08 2026 |
| E6660 | FMC-376 | FMC-376 is a selective and irreversible dual inhibitor of both the ON and OFF states of KRASG12C. It binds covalently to the mutant cysteine at position 12 in KRAS G12C and directly blocks both the ON and OFF conformations of the mutant KRAS protein, leading to a complete and durable blockade of downstream signaling. FMC‑376 exhibits robust anti‑tumor activity in vivo. | Apr 08 2026 |
| E5864 | EG01377 Dihydrochloride | EG01377 dihydrochloride is a potent, bioavailable, and selective inhibitor of neuropilin‑1 (NRP1), with a Kd of 1.32 μM and IC50 609 nM for both NRP1‑a1 and NRP1‑b1. It also exhibits antiangiogenic, antimigratory, and antitumor effects in vitro. | Apr 08 2026 |
| E1577 | AZD4747 | AZD4747 is a selective, blood‑brain barrier‑permeable inhibitor of mutant GTPase KRASG12C, with the potential to treat KRAS^G12C‑positive tumors, including central nervous system (CNS) metastases. | Apr 08 2026 |
| S7151 | Garcinol | Garcinol is a polyisoprenylated benzophenone compound isolated from the fruit rind of Garcinia indica. It acts as a potent natural inhibitor of histone acetyltransferases (HATs), including p300 and PCAF, with IC50 of ~7 μM and 5 μM, respectively. It also exhibits anti-cholinesterase activity against AChE and BChE with an IC50 of 0.66 μM and 7.39 μM, respectively. | Apr 08 2026 |
| E6681 | Tinlarebant | Tinlarebant (LBS-008; BPN-14967) is an oral, non‑retinoid antagonist of RBP4, which exhibits potential to treat Stargardt disease and advanced dry age‑related macular degeneration. | Apr 08 2026 |
| P1254 | Rusfertide(PTG-300) | Rusfertide (PTG-300) is a hepcidin mimetic that targets ferroportin, inducing its internalization and degradation to block cellular iron export into the blood. By limiting transferrin saturation (TSAT), it reduces systemic labile iron toxicity and prevents organ iron deposition. Rusfertide exhibits the potential treatment for Hereditary Hemochromatosis and hemoglobinopathies like beta-thalassemia and also helps to improve anemia by promoting more effective erythropoiesis. | Apr 06 2026 |
| E6700 | G-6599 | G-6599 is a potent monovalent degrader of SMARCA2/SMARCA4 that covalently binds a cysteine on E3 ligase FBXO22, forming a ternary complex for ubiquitin-proteasome degradation. It exhibits potential research applications in androgen-dependent prostate cancer and SMARCA4-mutant non-small cell lung cancer. | Apr 06 2026 |
| E6476 | SBI-810 hydrochloride | SBI‑810 hydrochloride is a β‑arrestin–biased, functionally selective allosteric modulator of neurotensin receptor 1 (NTSR1) that alters NTSR1‑mediated G protein signaling in a G protein–specific manner when the endogenous ligand neurotensin (NT) is present, fully antagonizing NT‑induced Gq activation, partially antagonizing Gi1 activation, and remaining permissive toward NTSR1‑mediated activation of GoA and G12. | Mar 30 2026 |
| E5769 | MY-1B | MY‑1B is a covalent inhibitor of the RNA methyltransferase NSUN2, with an IC50 of 1.3 μM. MY‑1B stereoselectively targets the active‑site cysteine residue C271 of NSUN2 and can be used to probe the function of NSUN2 in RNA methylation‑related processes. | Mar 29 2026 |
| S9814 | BMS-986202 | BMS‑986202 is a potent, selective and orally active inhibitor of TYK2 that binds to the TYK2 pseudokinase domain (JH2) with an IC50 of 0.19 nM and a Ki of 0.02 nM. | Mar 24 2026 |
| E1584 | CCR6 inhibitor 1 | CCR6 inhibitor-1 is a potent and selective inhibitor of CCR6 with IC50 of 0.45 nM and 6 nM for monkey and human CCR6, respectively. It potently inhibits human B-cell migration and ERK phosphorylation, exhibiting potential as a treatment for autoimmune diseases. | Mar 24 2026 |
| E4769 | Aleniglipron (GSBR-1290) | Aleniglipron (GSBR‑1290) is a potent, orally available agonist of GLP‑1R that selectively activates the Gαs–cAMP signaling pathway without detectable β‑arrestin recruitment. | Mar 24 2026 |
| E1097 | Famitinib (SHR1020) | Famitinib (SHR1020), an orally active inhibitor of multi‑targeted kinase, which inhibits the activity of c‑Kit, VEGFR‑2, and PDGFRβ with IC50 of 2.3 nM, 4.7 nM, and 6.6 nM, respectively. | Mar 23 2026 |
| E6693 | PKUMDL-WQ-2101 | PKUMDL‑WQ‑2101 is a non‑NAD⁺‑competing allosteric inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC50 of 34.8 μM. It exhibits antitumor activity, selectively inhibits de novo serine synthesis in cancer cells, and reduces tumor growth in vivo. | Mar 23 2026 |
| P1273 | Ecnoglutide（XW003） | Ecnoglutide (XW003) is a long‑acting, cAMP‑biased agonist of the glucagon‑like peptide‑1 (GLP‑1) receptor that selectively enhances cAMP signaling over β‑arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity. | Mar 23 2026 |
| E6703 | MLT-985 | MLT‑985 is a selective allosteric and orally active inhibitor of MALT1 with an IC50 of 3 nM. It inhibits MALT1‑dependent signaling in ABC‑DLBCL models and reduces cell growth and aberrant CARD11/BCL10/MALT1‑complex activity in vitro. | Mar 23 2026 |
| E1475 | CFT1946 (Tagarafdeg) | CFT1946 (Tagarafdeg) is an orally bioavailable, CRBN‑based bifunctional degradation‑activating compound (BiDAC) that selectively targets mutant BRAFV600E for ubiquitin–proteasome–mediated degradation, with a DC50 of 14 nM in A375 melanoma cells. | Mar 23 2026 |
| E6751 | Sodium iodoacetate(Iodoacetic acid sodium salt) | Sodium iodoacetate(Iodoacetic acid sodium salt) is a specific, covalent inhibitor of glyceraldehyde‑3‑phosphate dehydrogenase (GAPDH) that blocks glycolytic flux by alkylating the catalytic cysteine residue in the active site, thereby exerting glycolysis‑inhibitory activity in cells and tissues. It also induces osteoarthritis‑like joint degeneration and related pain models in experimental animals. | Mar 19 2026 |
| E6756 | MOCAc-PLGL(Dpa)AR | MOCAc-PLGL(Dpa)AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂) is a FRET-based fluorescent peptide substrate for MMPs including MMP-7 (matrilysin), MMP-2, and MMP-9, where the MOCAc fluorophore is quenched by Dpa until cleavage at the Gly-Leu bond produces >10-fold fluorescence increase for activity assays. | Mar 19 2026 |
| E6456 | PF-07248144(Prifetrastat) | PF‑07248144 (Prifetrastat) is a potent and selective catalytic inhibitor of KAT6A and KAT6B that exhibits durable antitumor activity and the potential to treat metastatic breast cancer. | Mar 16 2026 |
| F0806 | Phospho-VEGF Receptor 2 (Tyr1059) Antibody [J6L3] | Mar 12 2026 | |
| F1159 | Melanoma gp100 Antibody [K14B19] | Melanoma gp100,PMEL | Mar 12 2026 |
| F2141 | Phospho-ALK (Tyr1604) Antibody [G21H21] | ALK (phospho Y1604),Phospho-ALK (Tyr1604) | Mar 12 2026 |
| F2386 | M-CSF Antibody [K14B13] | CSF-1R/M-CSF-R,M-CSF | Mar 12 2026 |
| F2788 | Dopamine Transporter Antibody [A13P6] | Dopamine Transporter,SLC6A3/DAT1 | Mar 12 2026 |
| F2240 | Phospho-BRAF (Ser729) Antibody [H9E15] | Mar 12 2026 | |
| F3464 | Olfactory Marker Protein/OMP Antibody [J3H9] | Mar 12 2026 | |
| F3735 | Human IgG Antibody [H24A6] | Mar 12 2026 | |
| F3805 | Hepatitis C Virus Antibody [K15A4] | Mar 12 2026 | |
| F3503 | Insulin Receptor α Antibody [J24M5] | Insulin Receptor alpha,Insulin Receptor α | Mar 12 2026 |
| F4822 | BATF Antibody [C3L16] | Mar 12 2026 | |
| F1625 | LDL Receptor Antibody [G7A23] | LDL Receptor,LDLR | Mar 12 2026 |
| F1199 | Phospho-MLKL (Ser345) Antibody [G22F14] | MLKL (phospho S345),Phospho-MLKL (Ser345) | Mar 12 2026 |
| F0152 | Phospho-Akt (Ser473) Antibody [F14K15] | p-Akt1/2/3,phospho akt1/pkbalpha (ser473),Phospho-Akt (Ser473) | Mar 12 2026 |
| F4307 | TPR Antibody [B2D4] | Mar 12 2026 | |
| F2439 | Ym-1 + Ym-2 Antibody [C18B8] | Mar 12 2026 | |
| F4851 | MEK3 Antibody [B9B14] | Mar 12 2026 | |
| F4908 | GC1q R Antibody [E11B2] | Mar 12 2026 | |
| F2404 | Cyclophilin A Antibody [H11E16] | Mar 12 2026 | |
| F1953 | TIRAP Antibody [P21E21] | Mar 12 2026 | |
| F3182 | Tissue Plasminogen Activator Antibody [P14H9] | Tissue Plasminogen Activator,tPA,tPA (Tissue Plasminogen Activator) | Mar 12 2026 |
| F2542 | α1 Antitrypsin Antibody [L14P15] | Mar 12 2026 | |
| F3541 | Phospho-Akt (Thr308) Antibody [F21G22] | AKT (phospho T308),AKT1 (phospho T308),pan-AKT (phospho T308),Phospho-Akt (Thr308) | Mar 12 2026 |
| F3625 | TGIF Antibody [C15J1] | Mar 12 2026 | |
| F3657 | MC1-R Antibody [B5P9] | Mar 12 2026 | |
| F3708 | fetal hemoglobin Antibody [E16B15] | Mar 12 2026 | |
| F3736 | LYVE1 Antibody [P8K5] | LYVE1,LYVE-1 | Mar 12 2026 |
| F3726 | RNF7 Antibody [C21H21] | Mar 12 2026 | |
| F3709 | TLE 1 Antibody [A20D17] | Mar 12 2026 | |
| F4848 | PKCβ2 Antibody [J13H4] | Mar 12 2026 | |
| F5299 | KLF5 Antibody [P15F22] | Mar 12 2026 | |
| F3293 | HOXA5 Antibody [C16C3] | Mar 12 2026 | |
| F3398 | HNF4α Antibody [H2M8] | HNF-4-alpha,HNF4α,HNF-4α | Mar 12 2026 |
| F3025 | Phospho-Tau (Thr181) Antibody [B1L14] | Phospho-Tau (Thr181),Tau (phospho T181) | Mar 12 2026 |
| F3847 | MDH2 Antibody [G11D6] | Mar 12 2026 | |
| F0422 | Atg5 Antibody [A3G17] | APG5/ATG5,APG5L/ATG5,Atg5 | Mar 12 2026 |
| F3748 | Semaphorin 3A Antibody [A21D7] | SEMA3A,Semaphorin 3A | Mar 12 2026 |
| F4140 | IRF-3 Antibody [P4B7] | Mar 12 2026 | |
| F3742 | Sortilin/NT3 Antibody [M3F21] | Mar 12 2026 | |
| F3881 | IDH1 Antibody [A8P5] | Mar 12 2026 | |
| F4027 | MARCKS Antibody [D11P12] | Mar 12 2026 | |
| F4039 | Serotonin transporter Antibody [E20E5] | Mar 12 2026 | |
| F4178 | PI3 Kinase Class III Antibody [C6E8] | Mar 12 2026 | |
| F6032 | PTK7/CCK4 Antibody [B13K12] | Mar 12 2026 | |
| F8719 | LAMTOR5/HBXIP Antibody [L8H1] | Mar 12 2026 | |
| F3655 | UBA52 Antibody [B4F11] | Mar 12 2026 | |
| F9371 | ADAM9 Antibody [M15P12] | Mar 12 2026 | |
| F1616 | HLA A Antibody [F17H17] | Mar 12 2026 | |
| F4301 | E2A Antibody [E15P20] | Mar 12 2026 | |
| F4811 | MSH2 Antibody [D6C24] | Mar 12 2026 | |
| F4874 | FOXP1 Antibody [D17A18] | Mar 12 2026 | |
| F4162 | GOT2 Antibody [J21P14] | Mar 12 2026 | |
| F5029 | Thioredoxin 2 Antibody [B17P21] | Mar 12 2026 | |
| F4095 | S100A9 Antibody [K10G19] | Mar 12 2026 | |
| F5092 | PYCR1 Antibody [D14M24] | Mar 12 2026 | |
| F4098 | Perilipin-2 Antibody [D18L12] | Mar 12 2026 | |
| F4099 | Catenin δ-1 Antibody [M20J3] | Mar 12 2026 | |
| F5100 | KIF20A Antibody [M19G8] | Mar 12 2026 | |
| F5115 | MYL4 Antibody [K10N17] | Mar 12 2026 | |
| F9634 | Sharpin Antibody [G5P13] | Mar 12 2026 | |
| F7794 | PEX5 Antibody [L22A16] | Mar 12 2026 | |
| F4610 | CD133 Antibody [F19M17] | Mar 12 2026 | |
| F0820 | p38β MAPK Antibody [F9P5] | Mar 12 2026 | |
| F1177 | BRG1 Antibody [B13A6] | Brg1,Brg-1 | Mar 12 2026 |
| F2663 | Phospho-Paxillin (Tyr118) Antibody [H11B7] | Mar 12 2026 | |
| F2347 | AMPKγ1 Antibody [M8F13] | AMPK gamma 1,AMPKγ1 | Mar 12 2026 |
| F3121 | Claudin 4 Antibody [P2L10] | Mar 12 2026 | |
| F3750 | FOXL2 Antibody [L8H14] | Mar 12 2026 | |
| F0653 | Phospho-VEGF Receptor 2 (Tyr951) Antibody [F15G14] | Phospho-VEGF Receptor 2 (Tyr951),VEGF Receptor 2 (phospho Y951) | Mar 12 2026 |
| F2245 | RANKL Antibody [K7M17] | RANK Ligand (L300),RANK Ligand (R2),RANKL,sRANKL | Mar 12 2026 |
| F3347 | Phospho-Bad (Ser112) Antibody [F3L12] | Bad (phospho S112),Phospho-Bad (Ser112) | Mar 12 2026 |
| F3969 | Phospho-mTOR (Ser2481) Antibody [G3C12] | Mar 12 2026 | |
| F2677 | β Actin Antibody [H22G2] | ACTB,beta Actin,beta Actin Loading Control,beta-Actin,β-Actin | Mar 12 2026 |
| F2903 | CD46 Antibody [H10H10] | Mar 12 2026 | |
| F3916 | GRK1 Antibody [H20D23] | Mar 12 2026 | |
| F4000 | EGF Antibody [C19B23] | Mar 12 2026 | |
| F4002 | TrkA Antibody [F8E20] | Mar 12 2026 | |
| F4005 | ETS1 Antibody [D20N5] | Mar 12 2026 | |
| F4036 | Robo1 Antibody [A23H22] | Mar 12 2026 | |
| F4051 | Paxillin Antibody [J24H4] | Mar 12 2026 | |
| F4053 | TIAL1 Antibody [C19N17] | Mar 12 2026 | |
| F4122 | Phospho-Stat1 (Tyr701) Antibody [J2C2] | Mar 12 2026 | |
| F4194 | XIAP Antibody [L24L9] | Mar 12 2026 | |
| F4309 | Rac GAP1 Antibody [N8J10] | Mar 12 2026 | |
| F4365 | Kinesin heavy chain Antibody [C20E5] | Mar 12 2026 | |
| F4414 | CUL4A Antibody [M22F16] | Mar 12 2026 | |
| F4418 | StAR Antibody [F23D21] | Mar 12 2026 | |
| F4446 | ALDH1A1/2/3/ALDH2 Antibody [G9N14] | Mar 12 2026 | |
| F4611 | Neuropilin-1 Antibody [C24N3] | Mar 12 2026 | |
| F4631 | OB-Cadherin Antibody [N18A11] | Mar 12 2026 | |
| F4633 | Tau 4R Antibody [D18K9] | Mar 12 2026 | |
| F4634 | CAR Antibody [F8M8] | Mar 12 2026 | |
| F4654 | CD44 Antibody [M8L2] | Mar 12 2026 | |
| F4669 | Brg1 Antibody [D24D16] | Mar 12 2026 | |
| F4671 | ALDH1A1 Antibody [F4F17] | Mar 12 2026 | |
| F4686 | Toll-like Receptor 2 Antibody [M20D11] | Mar 12 2026 | |
| F4713 | NRF1 Antibody [A16D19] | Mar 12 2026 | |
| F4717 | TFIIB Antibody [H2N6] | Mar 12 2026 | |
| F4727 | PDK1 Antibody [M15P23] | Mar 12 2026 | |
| F4787 | Lin28A Antibody [J2N23] | Mar 12 2026 | |
| F4788 | MAG/GMA Antibody [E22A5] | Mar 12 2026 | |
| F4834 | Annexin A1/ANXA1 Antibody [H11G4] | Mar 12 2026 | |
| F4836 | EpCAM Antibody [A14P2] | Mar 12 2026 | |
| F4840 | Ionotropic Glutamate receptor 2 Antibody [P18H1] | Mar 12 2026 | |
| F4951 | RBM15 Antibody [B16G2] | Mar 12 2026 | |
| F4964 | Phospho-RIPK1 (Ser161) Antibody [A1A2] | Mar 12 2026 | |
| F4965 | USP8 Antibody [K18J18] | Mar 12 2026 | |
| F5001 | STEP Antibody [A7M19] | Mar 12 2026 | |
| F5005 | PTBP1 Antibody [L20G7] | Mar 12 2026 | |
| F5010 | CD63 Antibody [P10C2] | Mar 12 2026 | |
| F5016 | Pan-Cadherin Antibody [J6A2] | Mar 12 2026 | |
| F5019 | MLH1 Antibody [P20K16] | Mar 12 2026 | |
| F5022 | VCP Antibody [P13E12] | Mar 12 2026 | |
| F5057 | HSP27 Antibody [D13K14] | Mar 12 2026 | |
| F5061 | DPP4/CD26 Antibody [D2B15] | Mar 12 2026 | |
| F5102 | Myocilin Antibody [D9K2] | Mar 12 2026 | |
| F4004 | ATF1 Antibody [H17A19] | Mar 12 2026 | |
| F4650 | SUMO-1 Antibody [J20F23] | Mar 12 2026 | |
| F4219 | Phospho-RIP (Ser166) Antibody [J17A23] | Mar 12 2026 | |
| F4943 | Activated/monophosphorylated ERK1/2 Antibody [F9B19] | Mar 12 2026 | |
| F4193 | IL-6 Antibody [L17N21] | Mar 12 2026 | |
| F4398 | Laminin γ1/LAMC1 Antibody [J8N3] | Mar 12 2026 | |
| F4594 | Histone H3 (mono methyl Lys36) Antibody [D2L24] | Mar 12 2026 | |
| F5017 | Keratin 17/19 Antibody [L1M17] | Mar 12 2026 | |
| F3361 | 6X His tag Antibody [G4E22] | 6X His tag,6XHIS,6x-His Tag,His-Tag,polyHistidine | Mar 12 2026 |
| E5879 | Elinzanetant | Elinzanetant (NT-814; BAY3427080) is a nonhormonal dual antagonist of NK1/NK3 receptor that reduces GnRH pulsatility by blocking neurokinin B (NK3) and substance P (NK1) effects on the reproductive axis in KNDy neurons. | Mar 12 2026 |
| E1593 | Camlipixant | Camlipixant (BLU-5937) is a potent, selective, non-competitive antagonist that target P2X3 homotrimeric receptor, with an IC50 of 25 nM for hP2X3 homotrimeric form. | Mar 12 2026 |
| E8328 | Ro24-7429 | Ro24-7429 is a benzodiazepine derivative that acts as a potent, orally active antagonist of HIV-1's Tat transactivator protein, disrupting viral replication by inhibiting Tat-mediated transactivation of the HIV-1 long terminal repeat (LTR) promoter. It also inhibits RUNX1 (runt-related transcription factor 1), contributing to antifibrotic effects by reducing fibrosis markers in models like bleomycin-induced pulmonary fibrosis, alongside anti-inflammatory properties. | Mar 10 2026 |
| P1259 | Cagrilintide | Cagrilintide is a long-acting acylated amylin analogue functioning as a nonselective agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). Its dual action promotes satiety, slows gastric emptying, and reduces food intake through brain-mediated pathways with the potential to treat obesity. | Mar 10 2026 |
| E4671 | ML334 | ML334 (LH601A) is a potent, cell-permeable activator of NRF2 that disrupts the Keap1-NRF2 protein-protein interaction by binding the Keap1 Kelch domain with a Kd of 1 μM, promoting NRF2 nuclear translocation and antioxidant gene expression. | Mar 08 2026 |
| E6698 | STL1267 | STL1267 is a potent agonist of REV-ERB, with Ki of 0.16 µM for REV-ERBα that crosses the blood-brain barrier, enhancing NCoR corepressor recruitment to repress circadian and metabolic genes. | Mar 08 2026 |
| E6697 | PACMA 31 | PACMA 31 is an irreversible, orally active inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. It covalently binds PDI's active-site cysteines, inhibiting reductase/isomerase activity in a dose- and time-dependent manner per insulin aggregation assays. | Mar 01 2026 |
| E6661 | Ontunisertib | Ontunisertib (AGMB-129) is an oral, GI-restricted small molecule inhibitor of ALK5 (TGFβR1), exhibiting the potential to treat fibrostenosing Crohn’s disease (FSCD). It potently blocks pro-fibrotic TGFβ signaling locally in the GI tract via high first-pass metabolism. | Mar 01 2026 |
| E6659 | TYRA-200 | TYRA-200 is an orally bioavailable inhibitor of FGFR1/2/3 that exhibits potential to address clinically observed acquired resistance alterations in FGFR2, such as molecular brake and gatekeeper mutations. | Mar 01 2026 |
| F0854 | Phospho-IRAK4 (Thr345/Ser346) Antibody [G2K20] | Feb 28 2026 | |
| F0654 | Phospho-c-Kit (Tyr703) Antibody [K16C2] | c-Kit (phospho Y703),Phospho-c-Kit (Tyr703) | Feb 28 2026 |
| F1556 | Giantin (Golgi Marker) Antibody [F5N17] | Feb 28 2026 | |
| F1679 | Mouse IgG Antibody [B6P15] | Feb 28 2026 | |
| F2243 | Hepatitis C Virus NS3 Antibody [N19B24] | Feb 28 2026 | |
| F2998 | HIV1 Vif Antibody [P7N1] | Feb 28 2026 | |
| F2605 | Phospho-Tau (Ser422) Antibody [L19H1] | Feb 28 2026 | |
| F0652 | Phospho-TrkA (Y785)/TrkB (Y816) Antibody [G6J11] | Feb 28 2026 | |
| F3766 | MAP2 Antibody [N20A24] | MAP2,MAP-2,Microtubule-Associated Protein 2 (MAP2) | Feb 28 2026 |
| F3821 | Hepatitis C Virus Core Antigen Antibody [N23M4] | Feb 28 2026 | |
| F3556 | Phospho-FoxO1 (T24)/FoxO3a (T32) Antibody [M8K9] | Feb 28 2026 | |
| F3950 | Phospho-ErbB2/HER2 (Tyr1248) Antibody [F22D17] | Feb 28 2026 | |
| F3960 | Measles nucleoprotein Antibody [H14C20] | Feb 28 2026 | |
| F1578 | Phospho-mTOR (Ser2481) Antibody [H20P20] | mTOR (phospho S2481),Phospho-mTOR (Ser2481) | Feb 28 2026 |
| F4774 | Hepatitis B Virus Core Antigen Antibody [F18P11] | Feb 28 2026 | |
| F4625 | Phospho-c-Myc (Ser62) Antibody [M18C23] | Feb 28 2026 | |
| F3057 | Neurofibromin 1 Antibody [J9P10] | Neurofibromin,Neurofibromin 1 | Feb 28 2026 |
| F0728 | FGFR3 Antibody [G21B24] | FGF Receptor 3,FGFR3,FGFR-3 | Feb 28 2026 |
| F4699 | NEDD8 Antibody [F18P17] | Feb 28 2026 | |
| F4689 | Pim-1 Antibody [J10P8] | Feb 28 2026 | |
| F1608 | Cleaved PARP1 Antibody [K10A21] | Feb 28 2026 | |
| F1669 | Androgen Receptor (AR-V7 specific) Antibody [F19P24] | Feb 28 2026 | |
| F5021 | SH2D1A Antibody [C12N16] | Feb 28 2026 | |
| F2956 | Topoisomerase II α+β Antibody [L11B23] | Feb 28 2026 | |
| F2463 | FADD Antibody [P17H10] | Feb 28 2026 | |
| F4241 | SynGAP Antibody [F22M8] | Feb 28 2026 | |
| F1519 | Human Serum Albumin Antibody [L7A9] | ALB,ALB/Albumin,Albumin,Human Serum Albumin | Feb 28 2026 |
| F2474 | Phospho-c-Myc (Thr58) Antibody [L1K9] | c-Myc (phospho T58),Phospho-c-Myc (Thr58) | Feb 28 2026 |
| F4883 | Cdc6 Antibody [L3E6] | Feb 28 2026 | |
| F4265 | p57 Kip2 Antibody [E16C13] | Feb 28 2026 | |
| F4500 | Nek2 Antibody [A24K3] | Feb 28 2026 | |
| F4749 | M6PR Antibody [J18A13] | Feb 28 2026 | |
| F4172 | Argonaute-2 Antibody [K4M16] | Feb 28 2026 | |
| F4112 | ICOS Antibody [A13H14] | Feb 28 2026 | |
| F2478 | C4 binding protein/C4BPB Antibody [K15D12] | Feb 28 2026 | |
| F8550 | SET1A Antibody [K11A18] | Feb 28 2026 | |
| F6299 | MLL2 C-terminal Antibody [L16L11] | Feb 28 2026 | |
| F5660 | EZH1 Antibody [G17M2] | Feb 28 2026 | |
| F5322 | BRCC36 Antibody [M5D3] | Feb 28 2026 | |
| F7125 | LRSAM1 Antibody [K13D2] | Feb 28 2026 | |
| F7401 | SMARCD3/BAF60C Antibody [C13A4] | Feb 28 2026 | |
| F2775 | Phospho-Tau (Ser214) Antibody [M8H2] | Phospho-Tau (Ser214),Tau (phospho S214) | Feb 28 2026 |
| F4859 | VAMP2 Antibody [M16L18] | Feb 28 2026 | |
| F5124 | TMEM111 Antibody [B9P11] | Feb 28 2026 | |
| F7967 | DNA Ligase IV/LIG4 Antibody [H22J17] | Feb 28 2026 | |
| F8516 | Acetyl-β Catenin (Lys49) Antibody [N20A14] | Feb 28 2026 | |
| F1263 | RagC Antibody [H17M14] | Feb 28 2026 | |
| F7104 | MIST1/bHLHa15 Antibody [L9C15] | Feb 28 2026 | |
| F4629 | Rev-Erbα Antibody [N13G12] | Feb 28 2026 | |
| F4865 | Histone H3 (di methyl Lys79) Antibody [F10E18] | Feb 28 2026 | |
| F6850 | PSMD2 Antibody [B5P6] | Feb 28 2026 | |
| F4668 | c-Raf Antibody [K20J19] | Feb 28 2026 | |
| F4860 | Cytokeratin 7 Antibody [H19A10] | Feb 28 2026 | |
| F7245 | eIF6 Antibody [A13F7] | Feb 28 2026 | |
| F4896 | Presenilin 2 Antibody [M18A3] | Feb 28 2026 | |
| F6873 | COBRA1 Antibody [K14G15] | Feb 28 2026 | |
| F4875 | CEA/CD66e Antibody [D17P1] | Feb 28 2026 | |
| F8896 | CBX8 Antibody [E24E8] | Feb 28 2026 | |
| F5142 | TBC1D7 Antibody [D5H17] | Feb 28 2026 | |
| F5830 | Ribosomal Protein L26 Antibody [L15C18] | Feb 28 2026 | |
| F8455 | SDH5 Antibody [F15B20] | Feb 28 2026 | |
| F5051 | SMARCD1/BAF60A Antibody [H10L13] | Feb 28 2026 | |
| F5012 | CD86 Antibody [L10K15] | Feb 28 2026 | |
| F5027 | SIX2 Antibody [E17K9] | Feb 28 2026 | |
| F5031 | CBS Antibody [J23E1] | Feb 28 2026 | |
| F5099 | KGA/GAC Antibody [B11B5] | Feb 28 2026 | |
| F5053 | CDK5 Antibody [H9D2] | Feb 28 2026 | |
| F5056 | ERCC1 Antibody [E18K16] | Feb 28 2026 | |
| F9079 | RhoB Antibody [G12L1] | Feb 28 2026 | |
| F8198 | NPRL2 Antibody [L19L7] | Feb 28 2026 | |
| F8140 | Cyclin C Antibody [J7J21] | Feb 28 2026 | |
| F5125 | Alcohol dehydrogenase 1B Antibody [G20E17] | Feb 28 2026 | |
| F5872 | Sec61B Antibody [E5N6] | Feb 28 2026 | |
| F0150 | Phospho-4E-BP1 (Thr37/46) Antibody [E9G24] | Feb 28 2026 | |
| F0483 | Hamartin/TSC1 Antibody [N1E19] | Hamartin,Hamartin/TSC1 | Feb 28 2026 |
| F0346 | Phospho-PERK (Thr980) Antibody [E16F3] | Feb 28 2026 | |
| F2390 | Flotillin 2 Antibody [A21G15] | Flotillin 2/ESA,Flotillin-2 | Feb 28 2026 |
| F2217 | Bub1 Antibody [N20E21] | Feb 28 2026 | |
| F3029 | MRP4/ABCC4 Antibody [D3L18] | MRP4,MRP4/ABCC4 | Feb 28 2026 |
| F3023 | IL-6 Antibody [F4K18] | IL-6 | Feb 28 2026 |
| F3061 | IL-1β Antibody [J24M1] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1β | Feb 28 2026 |
| F2632 | BRCA1 Antibody [N12F20] | BRCA1 | Feb 28 2026 |
| F3067 | IL-1β Antibody [H12N7] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1β | Feb 28 2026 |
| F2594 | SCF Antibody [K20P17] | Feb 28 2026 | |
| F2836 | SHC Antibody [N2E16] | Feb 28 2026 | |
| F3557 | Phospho-EGF Receptor (Tyr1045) Antibody [F16D14] | Feb 28 2026 | |
| F3443 | Phospho-p130 (Ser672) Antibody [E21C6] | Feb 28 2026 | |
| F3613 | ATP1B2 Antibody [G17J5] | Feb 28 2026 | |
| F3889 | NFAT1 Antibody [L23B6] | Feb 28 2026 | |
| F4143 | Met Antibody [K15N1] | Feb 28 2026 | |
| F4012 | PI3 Kinase p85α Antibody [L7D21] | Feb 28 2026 | |
| F4019 | SIRT7 Antibody [J3K9] | Feb 28 2026 | |
| F4049 | PCK1 Antibody [D3C9] | Feb 28 2026 | |
| F4061 | APAF1 Antibody [L11A23] | Feb 28 2026 | |
| F4104 | IGF-1Rβ Antibody [G20F1] | Feb 28 2026 | |
| F4108 | CSF-1R/M-CSF-R Antibody [P4B9] | Feb 28 2026 | |
| F4354 | Macrophages/Monocytes Antibody [K8D24] | Feb 28 2026 | |
| F4069 | Rab9 Antibody [C1J10] | Feb 28 2026 | |
| F4163 | p22phox Antibody [G20B7] | Feb 28 2026 | |
| F4197 | DARPP32 Antibody [G9D16] | Feb 28 2026 | |
| F4206 | Aurora A Antibody [J10G23] | Feb 28 2026 | |
| F4211 | Claudin-1 Antibody [N2H22] | Feb 28 2026 | |
| F4729 | ATF-3 Antibody [D14J2] | Feb 28 2026 | |
| F4152 | Cyclin A2 Antibody [N5C11] | Feb 28 2026 | |
| F4224 | TNF-R1 Antibody [M22M6] | Feb 28 2026 | |
| F4243 | EBF1 Antibody [D5J14] | Feb 28 2026 | |
| F2137 | Bestrophin/BEST1 Antibody [B12E13] | Bestrophin 1,Bestrophin/BEST1 | Feb 28 2026 |
| F5060 | ATRX Antibody [B2B21] | Feb 28 2026 | |
| F4457 | PLCβ1 Antibody [N12B19] | Feb 28 2026 | |
| F4803 | CD36 Antibody [J12N24] | Feb 28 2026 | |
| F4818 | IP3 receptor Antibody [N14P12] | Feb 28 2026 | |
| F4587 | UNC5B Antibody [H18P14] | Feb 28 2026 | |
| F4691 | DUSP4 Antibody [F2A21] | Feb 28 2026 | |
| F4742 | N-Myc Antibody [C8B13] | Feb 28 2026 | |
| F4814 | SOX10 Antibody [E22E2] | Feb 28 2026 | |
| F4857 | Apolipoprotein E Antibody [L10K14] | Feb 28 2026 | |
| F4863 | iNOS Antibody [G10L10] | Feb 28 2026 | |
| F4873 | CD276 Antibody [P14M24] | Feb 28 2026 | |
| F4878 | TEAD1 Antibody [H6K12] | Feb 28 2026 | |
| F4485 | XRCC4 Antibody [N17K6] | Feb 28 2026 | |
| F4516 | ACK Antibody [B23C14] | Feb 28 2026 | |
| F4677 | TIM-3 Antibody [F19D23] | Feb 28 2026 | |
| F4685 | 5 Lipoxygenase/5-LO Antibody [G15A12] | Feb 28 2026 | |
| F4723 | UBE2I/UBC9 Antibody [P3K8] | Feb 28 2026 | |
| F4736 | PRMT4/CARM1 Antibody [J8A9] | Feb 28 2026 | |
| F4743 | β Arrestin 1 Antibody [A11H23] | Feb 28 2026 | |
| F4746 | Enolase-2 Antibody [F8D21] | Feb 28 2026 | |
| F4755 | CD62L/L-Selectin Antibody [H14P17] | Feb 28 2026 | |
| F4763 | Basic FGF Antibody [L15D6] | Feb 28 2026 | |
| F5088 | RGS2 Antibody [L2C7] | Feb 28 2026 | |
| F5091 | Transgelin 2 Antibody [D20N10] | Feb 28 2026 | |
| F4146 | Phospho-Stat5 (Tyr694) Antibody [L6J15] | Feb 28 2026 | |
| F4174 | Stat1 Antibody [G13B13] | Feb 28 2026 | |
| F4052 | PKM Antibody [F7K24] | Feb 28 2026 | |
| F3968 | Phospho-EGFR (Tyr1101) Antibody [A24A1] | Feb 28 2026 | |
| F4185 | Axl Antibody [P12M12] | Feb 28 2026 | |
| E4770 | Jedi2 | Jedi2 is an activator of the Piezo1 channel that binds to mouse Piezo1 protein with a Kd of 2770 μM. | Feb 27 2026 |
| E6712 | PYCR1-IN-1 | PYCR1-IN-1 (compound 4) is an inhibitor of pyrroline-5-carboxylate reductase 1 (PYCR1) with an IC50 of 8.8 µM. It significantly reduce the levels of proline within a breast cancer cell line and exhibits anti-cell proliferation effect. | Feb 26 2026 |
| E6708 | HQ461 | HQ461 is a molecular glue degrader that promotes CDK12-DDB1-CUL4-RBX1 interaction, causing polyubiquitination and degradation of Cyclin K (CCNK). HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death. | Feb 26 2026 |
- First Page
- Previous
-
- Next
- Last Page
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間